These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 22079718)
61. Drug-Polymer Interaction, Pharmacokinetics and Antitumor Effect of PEG-PLA/Taxane Derivative TM-2 Micelles for Intravenous Drug Delivery. Wang Q; Liu Y; Pu C; Zhang H; Tan X; Gou J; He H; Yin T; Zhang Y; Wang Y; Tang X Pharm Res; 2018 Sep; 35(11):208. PubMed ID: 30215146 [TBL] [Abstract][Full Text] [Related]
62. Is an alternative drug delivery system needed for docetaxel? The role of controlling epimerization in formulations and beyond. Manjappa AS; Goel PN; Vekataraju MP; Rajesh KS; Makwana K; Ukawala M; Nikam Y; Gude RP; Murthy RS Pharm Res; 2013 Oct; 30(10):2675-93. PubMed ID: 23756759 [TBL] [Abstract][Full Text] [Related]
63. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin. Kim H; Lee Y; Lee IH; Kim S; Kim D; Saw PE; Lee J; Choi M; Kim YC; Jon S J Control Release; 2014 Mar; 178():118-24. PubMed ID: 24462899 [TBL] [Abstract][Full Text] [Related]
64. Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles. Fu JY; Blatchford DR; Tetley L; Dufès C J Control Release; 2009 Dec; 140(2):95-9. PubMed ID: 19709637 [TBL] [Abstract][Full Text] [Related]
65. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. Liu J; Zahedi P; Zeng F; Allen C J Pharm Sci; 2008 Aug; 97(8):3274-90. PubMed ID: 18064681 [TBL] [Abstract][Full Text] [Related]
66. The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations. Tsallas A; Jackson J; Burt H Cancer Chemother Pharmacol; 2011 Aug; 68(2):431-44. PubMed ID: 21069339 [TBL] [Abstract][Full Text] [Related]
67. Enhanced docetaxel delivery using sterically stabilized RIPL peptide-conjugated nanostructured lipid carriers: In vitro and in vivo antitumor efficacy against SKOV3 ovarian cancer cells. Kim CH; Kang TH; Kim BD; Lee TH; Yoon HY; Goo YT; Choi YS; Kang MJ; Choi YW Int J Pharm; 2020 Jun; 583():119393. PubMed ID: 32376445 [TBL] [Abstract][Full Text] [Related]
68. Biodegradable self-assembled PEG-PCL-PEG micelles for hydrophobic honokiol delivery: I. Preparation and characterization. Gong C; Wei X; Wang X; Wang Y; Guo G; Mao Y; Luo F; Qian Z Nanotechnology; 2010 May; 21(21):215103. PubMed ID: 20431208 [TBL] [Abstract][Full Text] [Related]
69. Phytantriol Based "Stealth" Lyotropic Liquid Crystalline Nanoparticles for Improved Antitumor Efficacy and Reduced Toxicity of Docetaxel. Jain S; Bhankur N; Swarnakar NK; Thanki K Pharm Res; 2015 Oct; 32(10):3282-92. PubMed ID: 25968624 [TBL] [Abstract][Full Text] [Related]
70. Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel. Kim DH; Termsarasab U; Cho HJ; Yoon IS; Lee JY; Moon HT; Kim DD Int J Nanomedicine; 2014; 9():5711-27. PubMed ID: 25525355 [TBL] [Abstract][Full Text] [Related]
71. Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models. Yoo GH; Subramanian G; Piechocki MP; Ensley JF; Kucuk O; Tulunay OE; Lonardo F; Kim H; Won J; Stevens T; Lin HS Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):735-42. PubMed ID: 18645124 [TBL] [Abstract][Full Text] [Related]
72. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Yuan Q; Han J; Cong W; Ge Y; Ma D; Dai Z; Li Y; Bi X Int J Nanomedicine; 2014; 9():4829-46. PubMed ID: 25378924 [TBL] [Abstract][Full Text] [Related]
73. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel. Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643 [TBL] [Abstract][Full Text] [Related]
74. Polypeptide-based Micelles for Delivery of Irinotecan: Physicochemical and In vivo Characterization. Ramasamy T; Choi JY; Cho HJ; Umadevi SK; Shin BS; Choi HG; Yong CS; Kim JO Pharm Res; 2015 Jun; 32(6):1947-56. PubMed ID: 25471199 [TBL] [Abstract][Full Text] [Related]
75. Enhanced tolerance and antitumor efficacy by docetaxel-loaded albumin nanoparticles. Tang X; Wang G; Shi R; Jiang K; Meng L; Ren H; Wu J; Hu Y Drug Deliv; 2016 Oct; 23(8):2686-2696. PubMed ID: 26004129 [TBL] [Abstract][Full Text] [Related]
76. Stabilization and sustained release of zeylenone, a soft cytotoxic drug, within polymeric micelles for local antitumor drug delivery. Hu X; Han R; Quan LH; Liu CY; Liao YH Int J Pharm; 2013 Jun; 450(1-2):331-7. PubMed ID: 23587966 [TBL] [Abstract][Full Text] [Related]
77. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070 [TBL] [Abstract][Full Text] [Related]
78. Preparation of HIFU-triggered tumor-targeted hyaluronic acid micelles for controlled drug release and enhanced cellular uptake. Zheng S; Jin Z; Han J; Cho S; Nguyen VD; Ko SY; Park JO; Park S Colloids Surf B Biointerfaces; 2016 Jul; 143():27-36. PubMed ID: 26998864 [TBL] [Abstract][Full Text] [Related]
79. Injectable and biodegradable poly(organophosphazene) hydrogel as a delivery system of docetaxel for cancer treatment. Cho JK; Hong JM; Han T; Yang HK; Song SC J Drug Target; 2013 Jul; 21(6):564-73. PubMed ID: 23594096 [TBL] [Abstract][Full Text] [Related]
80. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]